JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
A phase 3 trial testing JSKN003 in HER2-positive breast cancer, now recruiting.
Overview
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer is a phase 3 interventional study registered as NCT06846437, led by Shanghai JMT-Bio, and recruiting when checked on 2026-09-11. Official title: A Randomised, Controlled, Open-Label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Subjects. Planned enrolment is 228 participants (estimated). The study started in 2025-02-18 and primary completion is expected in 2026-10-13. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer and the tag ctgov-ingest.
- TrialJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Shares JSKN003 and the tag ctgov-ingest.
- TrialA Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer and the tag ctgov-ingest.
- TrialA Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Shares CSPC Pharmaceutical Group and the tag ctgov-ingest.
- TrialPhase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
Shares CSPC Pharmaceutical Group and the tag ctgov-ingest.
- TrialA Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialIBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.